Tamoxifen

Denosumab Shows Promise as Immune Modulator in Breast Cancer Treatment

6 days ago

• The D-BIOMARK clinical trial reveals that denosumab, commonly used for osteoporosis and bone complications, enhances immune cell infiltration in breast cancer tumors despite showing no direct anti-proliferative effects. • The drug's immune-boosting properties were most pronounced in luminal B breast cancer, a subtype that typically responds poorly to current immunotherapies, potentially opening new treatment avenues. • Researchers from ICO, IDIBELL, and CNIO collaborated on this study, demonstrating how denosumab inhibits the RANK pathway, which plays a key role in breast cancer development and progression.

ARX788 Demonstrates Significant PFS Benefit in HER2-Positive Breast Cancer

4 months ago

• A phase III trial of ARX788 showed a significantly longer median progression-free survival (PFS) of 11.3 months compared to 8.2 months with lapatinib plus capecitabine (LC) in HER2-positive advanced breast cancer patients. • The objective response rate (ORR) was higher in the ARX788 group (63.8%) compared to the LC group (52.7%), with a significantly longer duration of response (DoR) of 12.5 months versus 8.3 months. • ARX788 demonstrated a manageable safety profile, with the most frequent treatment-related adverse events (TRAEs) including hepatic enzyme increase, dry eye, blurred vision, alopecia, and interstitial lung disease (ILD). • The study suggests ARX788 could be an alternative second-line treatment option for HER2-positive advanced breast cancer patients who have progressed on trastuzumab and taxane.

Pfizer's Sasanlimab Plus BCG Shows Promise in BCG-Naive, High-Risk NMIBC

4 months ago

• Pfizer's Phase 3 CREST trial showed that sasanlimab combined with BCG significantly improved event-free survival in BCG-naive, high-risk NMIBC patients. • The combination therapy demonstrated a clinically meaningful and statistically significant improvement compared to BCG alone in the study. • Sasanlimab's safety profile in combination with BCG was consistent with the known profiles of both agents, according to the trial data. • Pfizer plans to submit the CREST trial results for presentation at an upcoming medical congress and discuss potential regulatory filings.

Advancements in Breast Cancer Research Unveiled at SABCS 2024

5 months ago

• The PATINA trial suggests palbociclib with anti-HER2 and endocrine therapy may become a new standard for HR+, HER2+ metastatic breast cancer. • COMET trial indicates active monitoring is comparable to surgery for low-risk DCIS, offering a potential alternative management option. • OlympiA trial's long-term results reinforce olaparib's role in preventing recurrence and highlight the importance of BRCA testing for early-stage breast cancer.

SABCS 2024: Key Advances in Breast Cancer Treatment Highlighted

5 months ago

• Patritumab deruxtecan shows sustained responses with fewer toxicities compared to chemotherapy in neoadjuvant treatment for early breast cancer. • Olaparib demonstrates long-term efficacy in patients with HER2-negative, high-risk breast cancer harboring BRCA1/2 mutations, improving invasive and distant disease-free survival. • Fam-trastuzumab deruxtecan-nxki (T-DXd) improves progression-free survival compared to physician's choice of therapy in HR-positive, HER2-low metastatic breast cancer. • Immediate surgery reduces local recurrence in elderly breast cancer patients, while active monitoring proves non-inferior to standard treatment in low-risk DCIS.

EUROPA Trial: Radiotherapy Preserves Quality of Life Better Than Endocrine Therapy in Older Breast Cancer Patients

5 months ago

• Interim analysis of the EUROPA trial reveals that radiotherapy is associated with better health-related quality of life (HRQOL) compared to endocrine therapy in older women with low-risk early breast cancer. • The study, involving 731 women aged 70 and older, assessed HRQOL using the EORTC QOL Questionnaire-30, showing a smaller decline in global health status in the radiotherapy group at 24 months. • Treatment-related adverse events were more frequent in the endocrine therapy group, with higher rates of arthralgia, fatigue, and hot flashes, leading to more treatment discontinuations. • Researchers suggest radiotherapy may be a less burdensome alternative, but emphasize the need for further data on disease control outcomes to draw definitive conclusions.

Daré Bioscience Advances Women's Health Portfolio with Funding and Clinical Progress

6 months ago

• Daré Bioscience is progressing its hormone-free contraceptive, Ovaprene, in a Phase 3 efficacy study, boosted by a foundation grant to expand clinical sites. • Sildenafil Cream 3.6% for female sexual arousal disorder is advancing towards Phase 3 after constructive FDA discussions on trial design and endpoints. • DARE-HPV, a novel treatment for HPV-related cervical diseases, is set for a Phase 2 trial, supported by a $10 million ARPA-H award. • Activities are underway for Phase 2 and Phase 1 studies of DARE-VVA1 and DARE-PTB1, respectively, targeting dyspareunia and preterm birth prevention.

Astellas' Fezolinetant Enters Phase 3 Trial for VMS in Breast Cancer Patients on Endocrine Therapy

9 months ago

• Astellas has initiated a Phase 3 trial (HIGHLIGHT 1) to evaluate fezolinetant for moderate to severe vasomotor symptoms (VMS) in breast cancer patients receiving adjuvant endocrine therapy. • The trial aims to enroll approximately 540 women with stage 0-3 hormone receptor-positive breast cancer across 100 global sites, comparing fezolinetant to placebo. • Fezolinetant, a nonhormonal oral medication, targets neurokinin B (NKB) to help restore balance in the brain's temperature control center, potentially reducing hot flashes and night sweats. • The primary endpoints of the HIGHLIGHT 1 study are changes in the frequency and severity of VMS at weeks 4 and 12, with treatment duration of 52 weeks and final evaluation at 55 weeks.

Drug Development Updates